List of Excipients in Branded Drug CARVEDILOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Apotex Corp	CARVEDILOL PHOSPHATE	carvedilol phosphate	60505-3678	CELLULOSE, MICROCRYSTALLINE
Apotex Corp	CARVEDILOL PHOSPHATE	carvedilol phosphate	60505-3678	CROSPOVIDONE
Apotex Corp	CARVEDILOL PHOSPHATE	carvedilol phosphate	60505-3678	HYDROGENATED CASTOR OIL
Apotex Corp	CARVEDILOL PHOSPHATE	carvedilol phosphate	60505-3678	MAGNESIUM STEARATE
Apotex Corp	CARVEDILOL PHOSPHATE	carvedilol phosphate	60505-3678	POVIDONE

Generic Drugs Containing CARVEDILOL

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA, Inc.	carvedilol	0093-0051	CROSPOVIDONE
Teva Pharmaceuticals USA, Inc.	carvedilol	0093-0051	HYPROMELLOSE 2910
Teva Pharmaceuticals USA, Inc.	carvedilol	0093-0051	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA, Inc.	carvedilol	0093-0051	MAGNESIUM STEARATE
Teva Pharmaceuticals USA, Inc.	carvedilol	0093-0051	POLYETHYLENE GLYCOL 400

What are the Most Frequently-Used Excipients in CARVEDILOL?

# Of NDCs	Excipient
2	AMINOLEVULINIC ACID HYDROCHLORIDE
2	AMINOMETRADINE
2	AMINOPENTAMIDE SULFATE
2	AMINOPHYLLINE
2	AMINOPROMAZINE

Excipient Strategy and Commercial Opportunities for Carvedilol

Last updated: February 27, 2026

What is the current excipient landscape for Carvedilol?

Carvedilol, a non-selective beta-blocker with alpha-1 blocking activity, is administered orally. Its formulation typically includes excipients such as microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and film-coating agents. These excipients stabilize the active pharmaceutical ingredient (API), facilitate drug release, and enhance stability.

How does excipient selection impact formulation development?

• Bioavailability: Carvedilol exhibits poor water solubility, leading to variable absorption. Using excipients like surfactants or solubilizers (e.g., polysorbates, polyethylene glycols) can improve dissolution.
• Stability: Excipients such as antioxidants (ascorbic acid) protect against oxidative degradation.
• Manufacturability: Excipients influence processability—compressibility, flowability, and granulation properties—key factors affecting manufacturing yield.

What strategies optimize excipient choice?

1. Solubilizing Excipients: Incorporate surfactants or lipid-based excipients to enhance solubility.
2. Controlled-Release Matrix: Use polymers like hydroxypropyl methylcellulose (HPMC) or ethylcellulose for sustained-release formulations.
3. Disintegrants: Select fast-acting disintegrants to promote rapid drug release in immediate-release products.
4. Stabilizers: Incorporate antioxidants and pH modifiers to prevent API degradation.

What commercial opportunities arise from excipient innovation?

• Enhanced Bioavailability: Formulations with novel excipients can improve absorption, enabling lower dosing and better patient compliance.
• Transdermal and Alternative Delivery: Developing patches, gels, or implantables utilizing excipients compatible with these routes expands market scope.
• Formulation Patents: Unique excipient combinations or controlled-release systems can secure patent protection, prolonging market exclusivity.
• Cost Reduction: Optimized excipient blends can streamline manufacturing, lowering production costs.
• Market Differentiation: Proprietary excipient systems offer a competitive edge in marketing bioavailability claims or dosing convenience.

Regulatory and supply chain considerations

• Excipient Safety: Must meet pharmacopoeial standards; new excipients require safety data.
• Supply Chain Reliability: Established excipients like lactose or microcrystalline cellulose benefit from a stable supply chain.
• Patent Landscape: Patent protection for novel excipient combinations may face challenges; patent clarity is essential.

Opportunities in excipient research and development

• Bioavailability Enhancers: Developing excipients that improve solubility can expand indications, such as in lower dose or pediatric formulations.
• Patient-Friendly Formulations: Excipient choices that reduce pill size or taste-masking improve adherence.
• Sustainability: Use of biodegradable or plant-derived excipients aligns with environmental trends, appealing to eco-conscious markets.

Comparison with other beta-blockers

Item	Conventional Carvedilol Formulation	Novel Excipient Approaches
Bioavailability	Variable	Increased via solubilizers
Release Profile	Immediate-release	Sustained or targeted release
Manufacturing Cost	Moderate	Potentially lower with optimized excipients

Key Takeaways

• Excipient strategies for Carvedilol focus on improving solubility, stability, and patient compliance.
• Innovations enable formulation-specific advantages such as enhanced bioavailability and controlled release.
• Patent opportunities stem from proprietary excipient combinations and delivery systems.
• Cost efficiency and supply chain stability should guide excipient selection.
• New excipient research can support broader indication expansion and alternative delivery routes.

FAQs

1. What excipients are most common in Carvedilol formulations?
   Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and film-coating agents are standard.

2. Can novel excipients improve Carvedilol bioavailability?
   Yes. Solubilizers and permeation enhancers can increase absorption, reducing dose and improving efficacy.

3. What are risks associated with new excipient use?
   Regulatory delays, safety validation requirements, and supply chain uncertainties pose challenges.

4. Are there patented excipient systems for Carvedilol?
   Some formulations involve proprietary controlled-release matrices, but specific excipient combinations are often unpatented or open.

5. How do excipient choices influence regulatory approval?
   Excipients must comply with pharmacopoeial standards; novel excipients require extensive safety data, potentially delaying approval.

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Safety Evaluation of Excipient Ingredients.
[2] European Medicines Agency. (2023). Guideline on Quality of Oral Modified Release Dosage Forms.
[3] Kearney, P. M., et al. (2020). Advances in formulation strategies for improving bioavailability of poorly water-soluble drugs. International Journal of Pharmaceutics, 583, 119410.